Surprisingly, another recent study shows that overexpression of P-gp (ABCB1) defines a subpopulation of MM cells which are resistant to carflizomib, the newly FDA-approved second generation proteasome inhibitor [102]. Here, PGP is linked to Miyoshi myopathy.